Cargando…

Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study

BACKGROUND: The purpose of this study was to evaluate change in glycosylated hemoglobin (HbA1c), side effects, and quality of life (QOL) after a 16-week treatment period with Biphasic insulin aspart 30/70 (BIasp30) in patients with type 2 diabetes mellitus (T2DM) who had been suboptimally controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Kee-Ho, Kim, Jung Min, Noh, Jung-Hyun, Park, Yongsoo, Son, Hyun-Shik, Min, Kyong Wan, Ko, Kyung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638222/ https://www.ncbi.nlm.nih.gov/pubmed/23641352 http://dx.doi.org/10.4093/dmj.2013.37.2.117

Ejemplares similares

Response: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
por: Song, Kee-Ho, et al.
Publicado: (2013)

Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013;37:117-24)
por: Lee, Byung-Wan
Publicado: (2013)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
por: Margaritidis, Charalampos, et al.
Publicado: (2021)

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
por: Liebl, Andreas, et al.
Publicado: (2018)

Efficacy and safety of patient‐directed titration of once‐daily pre‐dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP‐AKITA study
por: Narita, Takuma, et al.
Publicado: (2011)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
por: Ohta, Akio, et al.
Publicado: (2011)

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
por: Murthy, Sreenivasa, et al.
Publicado: (2021)

28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Assessment of biphasic calcium phosphate 70/30 alginate scaffold on the tibia in pigs
por: Soeyono, Gunanti, et al.
Publicado: (2020)

Ten Years of Experience with Biphasic Insulin Aspart 30: From Drug Development to the Latest Clinical Findings
por: Liebl, Andreas, et al.
Publicado: (2012)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A(1)chieve study
por: Das, A. K., et al.
Publicado: (2015)

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2013)

Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study
por: Shanmugasundar, G., et al.
Publicado: (2012)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
por: Shah, S, et al.
Publicado: (2009)

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)
por: Aravind, S. R., et al.
Publicado: (2022)

National Endoscopy Quality Improvement Program Remains Suboptimal in Korea
por: Cha, Jae Myung, et al.
Publicado: (2016)

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
por: Raja-Khan, Nazia, et al.
Publicado: (2007)

Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
por: Xu, Shaoyong, et al.
Publicado: (2016)

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
por: Aravind, S. R., et al.
Publicado: (2022)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Switching from basal or basal-bolus insulin to biphasic insulin aspart 30: Results from the Indian cohort of the A(1) chieve study
por: Bhattacharyya, Arpandev, et al.
Publicado: (2014)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

Comparative study of the usefulness of a novel insulin therapy in Japanese patients with Type 2 diabetes for concomitant use of an oral antidiabetic agent with twice-daily dosing either of insulin aspart, biphasic insulin aspart-30, or insulin detemir: Two times Insulin injection Combined with oral therapy Efficacy Study (TWICE study)
por: Itoh, Mitsuyasu, et al.
Publicado: (2021)

Suboptimal control status of young hypertensive population
por: Shin, Donghun, et al.
Publicado: (2023)

Comparative evaluation of biphasic calcium phosphate and biphasic calcium phosphate collagen composite on osteoconductive potency in rabbit calvarial defect
por: Lee, Eun-Ung, et al.
Publicado: (2015)

Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013: Nationwide population-based cohort study
por: Ko, Seung-Hyun, et al.
Publicado: (2016)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
por: Franek, E., et al.
Publicado: (2015)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A(1)chieve® observational study
por: Yang, Wenying, et al.
Publicado: (2014)

Suboptimal Management Status of Younger Hypertensive Population in Korea
por: Lee, Hae-Young, et al.
Publicado: (2021)

Biphasic human insulin 30 thrice daily, is it reasonable?
por: Saadeh, Nesreen A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o4v4lto6blhkubqft7cuhqdd9n